Out-of-pocket expenditures in France to manage psoriasis in adult patients: results from an observational, cross-sectional, non-comparative, multicentre study.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
20
05
2020
accepted:
05
10
2020
pubmed:
20
10
2020
medline:
15
5
2021
entrez:
19
10
2020
Statut:
ppublish
Résumé
In 2018 in France, overall mean health-related out-of-pocket (OOP) expenditures were 214.00€/year/patient. To evaluate OOP expenditures for psoriasis patients in France. Observational, cross-sectional, non-comparative, multicentre study in 3000 patients with clinically confirmed psoriasis who responded to a specific digital questionnaire collecting demographic and socio-economic characteristics, assessing the 3 domains (severity, psychosocial impact and past history and interventions) of the patient's Simplified Psoriasis Index (sa-SPI) and expenditures to manage psoriasis, including OOP. Multivariate linear regression was conducted to search for factors associated with higher OOP. In total, 2681 patients completed the questionnaire and, of those, 2562 provided clinically validated data. Overall, 60% were women; the mean age was 49.4 ± 14.8 years. 30% of the patients declared that they suffered from psoriatic arthritis. The final mean sa-SPI core was 10.86 ± 9.70. Of these 2562 patients, 243 (9.5%) had severe, 442 (17.3%) moderate and 1877 (73.3%) mild psoriasis. In addition, 932 (36.4%) patients reported facial involvement, 724 (28.25%) genital impairment and 1124 (43.8%) lesions on the limbs. Mean OOP expenditures to manage psoriasis per patient were 531.00€, 439.74€ ± 939.85€ for patients with mild, 791.06€ ± 1367.67€ with moderate and 1077.64€ ± 1680.14€ for patients with severe psoriasis. For patients with psoriasis in the genital area, the median amount of expenditures (251.17€; CI95% [138.35;363.99]) was significantly higher than that for the face (183.85€; CI95% [78.76;288.94]) or limbs (199.96€; CI95% [93.77;306.15); (P < 0.001). More than 90% of the patients had OOP expenditures for over-the-counter products (97.5%) and alternative care (92.0%), especially for emollients and/or hydrating products. In France, in 2019, OOP expenditures to manage psoriasis were on average more than twice as high as the overall mean health-related OOP expenditures estimated by the French Health Agency in 2018. These results should lead health authorities to review certain standards of healthcare reimbursement.
Sections du résumé
BACKGROUND
BACKGROUND
In 2018 in France, overall mean health-related out-of-pocket (OOP) expenditures were 214.00€/year/patient.
AIM
OBJECTIVE
To evaluate OOP expenditures for psoriasis patients in France.
METHODOLOGY
METHODS
Observational, cross-sectional, non-comparative, multicentre study in 3000 patients with clinically confirmed psoriasis who responded to a specific digital questionnaire collecting demographic and socio-economic characteristics, assessing the 3 domains (severity, psychosocial impact and past history and interventions) of the patient's Simplified Psoriasis Index (sa-SPI) and expenditures to manage psoriasis, including OOP. Multivariate linear regression was conducted to search for factors associated with higher OOP.
RESULTS
RESULTS
In total, 2681 patients completed the questionnaire and, of those, 2562 provided clinically validated data. Overall, 60% were women; the mean age was 49.4 ± 14.8 years. 30% of the patients declared that they suffered from psoriatic arthritis. The final mean sa-SPI core was 10.86 ± 9.70. Of these 2562 patients, 243 (9.5%) had severe, 442 (17.3%) moderate and 1877 (73.3%) mild psoriasis. In addition, 932 (36.4%) patients reported facial involvement, 724 (28.25%) genital impairment and 1124 (43.8%) lesions on the limbs. Mean OOP expenditures to manage psoriasis per patient were 531.00€, 439.74€ ± 939.85€ for patients with mild, 791.06€ ± 1367.67€ with moderate and 1077.64€ ± 1680.14€ for patients with severe psoriasis. For patients with psoriasis in the genital area, the median amount of expenditures (251.17€; CI95% [138.35;363.99]) was significantly higher than that for the face (183.85€; CI95% [78.76;288.94]) or limbs (199.96€; CI95% [93.77;306.15); (P < 0.001). More than 90% of the patients had OOP expenditures for over-the-counter products (97.5%) and alternative care (92.0%), especially for emollients and/or hydrating products.
CONCLUSION
CONCLUSIONS
In France, in 2019, OOP expenditures to manage psoriasis were on average more than twice as high as the overall mean health-related OOP expenditures estimated by the French Health Agency in 2018. These results should lead health authorities to review certain standards of healthcare reimbursement.
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
912-918Subventions
Organisme : Emma Clinic for Novartis
Informations de copyright
© 2020 European Academy of Dermatology and Venereology.
Références
Myers WA, Gottlieb AB, Mease P. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol 2006; 24: 438-447.
Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-850.
Green L, Meyers OL, Gordon W, Briggs B. Arthritis in psoriasis. Ann Rheum Dis 1981; 40: 366-369.
Eder L, Haddad A, Rosen CF, Lee KA, Chandran V, Cook R et al. The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. Arthritis Rheumatol 2016; 68: 915-923.
Richard MA, Corgibet F, Beylot-Barry M, Barbaud A, Bodemer C, Chaussade V et al. Sex- and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the << OBJECTIFS PEAU >> study. J Eur Acad Dermatol Venereol 2018; 32: 1967-1971.
Menter A, Gold LS, Bukhalo M, Grekin S, Kempers S, Boyce BM et al. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial. J Drugs Dermatol 2013; 12: 92-98.
Samarasekera E, Sawyer L, Parnham J, Smith CH. Assessment and management of psoriasis: summary of NICE guidance. BMJ 2012; 345: e6712.
Dauden E, Bewley A, Lambert J, Girolomoni G, Cambazard F, Reich K. Expert recommendations: the use of the fixed combination calcipotriol and betamethasone dipropionate gel for the topical treatment of psoriasis. J Eur Acad Dermatol Venereol 2014; 28(Suppl 2): 22-32.
Hendriks AG, Keijsers RR, de Jong EM, Seyger MM, van de Kerkhof PC. Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2013; 27: 931-951.
Luger T, Seite S, Humbert P, Krutmann J, Triller R, Dreno B. Recommendations for adjunctive basic skin care in patients with psoriasis. Eur J Dermatol 2014; 24: 194-200.
Launois R, Ezzedine K, Cabout E, Reguai Z, Merrhand S, Heas S et al. Importance of out-of-pocket costs for adult patients with atopic dermatitis in France. J Eur Acad Dermatol Venereol 2019; 33: 1921-1927.
Chularojanamontri L, Griffiths CE, Chalmers RJ. The Simplified Psoriasis Index (SPI): a practical tool for assessing psoriasis. J Invest Dermatol 2013; 133: 1956-1962.
Chularojanamontri L, Griffiths CEM, Chalmers RJG. Responsiveness to change and interpretability of the simplified psoriasis index. J Invest Dermatol 2014; 134: 351-358.
Zink AGS, Arents B, Fink-Wagner A, Seitz IA, Mensing U, Wettemann N et al. Out-of-pocket costs for individuals with atopic eczema: a cross-sectional study in Nine European countries. Acta Derm Venereol 2019; 99: 263-267.
Yeung K, Barthold D, Dusetzina SB, Basu A. Patient and plan spending after state specialty-drug out-of-pocket spending caps. N Engl J Med 2020; 383: 558-566.
Murage MJ, Gilligan AM, Tran O, Goldblum O, Burge R, Lin CY et al. Ixekizumab treatment patterns and healthcare utilization and costs for patients with psoriasis. J Dermatol Treat 2019; 1-8.
Saeki H, Ishii K, Joshi A, Bensimon AG, Yang H, Kawaguchi I. An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan. J Dermatolog Treat 2020; 1-11.
Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Naim A, Lofland JH. The direct healthcare insurer and out-of-pocket expenditures of psoriasis: evidence from a United States national survey. J Dermatolog Treat 2012; 23: 240-254.
Jungen D, Augustin M, Langenbruch A, Zander N, Reich K, Strömer K et al. Cost-of-illness of psoriasis - results of a German cross-sectional study. J Eur Acad Dermatol Venereol 2018; 32: 174-180.
Jenner N, Campbell J, Plunkett A, Marks R. Cost of psoriasis: a study on the morbidity and financial effects of having psoriasis in Australia. Australas J Dermatol 2002; 43: 255-261.
Navarini AA, Laffitte E, Conrad C, Piffaretti P, Brock E, Ruckdaeschel S et al. Estimation of cost-of-illness in patients with psoriasis in Switzerland. Swiss Med Wkly 2010; 140: 85-91.
Van Onselen J. An overview of psoriasis and the role of emollient therapy. Br J Community Nurs 2013; 18: 174-179.
Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris-Update 2015-Short version-EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2015; 29: 2277-2294.
Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol 2014; 70: 871-881.e1-30.